Drug Discovery

Unlocking the potential of GPCRs to structure-based drug design and creating transformative medicines.

Drug Discovery

Our world-leading and proprietary NxWave™ platform encompasses our patient-driven discovery approach, enabling us to unlock the potential of GPCRs to rational structure-based drug design (SBDD) and develop life-changing medicines. Our NxWave™ platform has 5 main steps:

Step 1

Target Identification and Validation

We identify and validate GPCR drug targets that we believe provide the best opportunity to develop novel medicines to transform the lives of patients and have strong commercial prospects. Our target identification and validation strategy looks at key factors, including:

Unmet patient need in our core disease areas of neurology, GI and immunology, metabolic disorders and rare diseases

Focus on targets with mechanism of action demonstrating a clear link between biological function and diseases

Commercially attractive, highly differentiated with a clear development path

Unmet patient need in our core disease areas of neurology, GI and immunology, metabolic disorders and rare diseases

Step 2

NxStaR

At the core of our approach is our world-leading NxStaR technology platform. NxStaR enables us to determine and analyse with unprecedented accuracy the structure of our target GPCRs using X-ray crystallography and cryo-electron microscopy, among other techniques.

Step 3

NxHit

NxHit covers a range of unique approaches to the identification of new compounds including:

Virtual screening
Screening of our custom-built GPCR-focused compound library
DEL screening utilizing NxStar

Step 4

NxDesign

This high-quality, high-resolution structural data enables our NxDesign SBDD approach, which coupled with our expertise in chemistry, pharmacology, drug metabolism and pharmacokinetics, computational chemistry and machine learning, allows us to precisely design therapeutic candidates with optimized target product profiles.

Step 5

Translational Medicine

Once we have promising preclinical candidates, our team of translational medicine and clinical development experts focus on designing and executing preclinical safety and clinical proof-of-mechanism studies to enable informed decisions on program progression.